Decoy Therapeutics (NASDAQ:DCOY) Stock Short Interest Rises 1,321.2%

Decoy Therapeutics (NASDAQ:DCOY) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 150,336 shares, a growth of 1,321.2% from the September 15th total of 10,578 shares. Based on an average trading volume of 11,986,981 shares, the short-interest ratio is currently 0.0 days. Currently, 23.3% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Decoy Therapeutics in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Decoy Therapeutics Trading Down 3.3%

Shares of NASDAQ:DCOY traded down $0.05 on Friday, hitting $1.47. 43,686 shares of the company were exchanged, compared to its average volume of 850,663. Decoy Therapeutics has a 1-year low of $1.46 and a 1-year high of $55.92. The stock’s 50 day moving average price is $2.94 and its 200 day moving average price is $4.99. The firm has a market capitalization of $962,850.00, a P/E ratio of -0.05 and a beta of 0.65.

Decoy Therapeutics (NASDAQ:DCOY) last released its earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter. On average, equities analysts predict that Decoy Therapeutics will post -8.96 EPS for the current fiscal year.

Decoy Therapeutics Company Profile

Decoy Therapeutics, Inc is a biotechnology company focused on discovering and developing antiviral medicines. The company’s research is based on the use of engineered “decoy” molecules designed to interfere with interactions between viruses and human cells, with the goal of preventing viral infection or limiting disease progression.

Decoy Therapeutics is developing a pipeline of investigational therapies intended to address viral diseases. Its platform is focused on creating treatments that may have activity against multiple viral strains or variants, although specific products, development stages and commercialization plans may change as the company advances its research programs.

Publicly available information about Decoy Therapeutics’ leadership, operating geographies and corporate history is limited.